Literature DB >> 29866947

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Maura L Gillison1, George Blumenschein2, Jerome Fayette3, Joel Guigay4, A Dimitrios Colevas5, Lisa Licitra6, Kevin J Harrington7, Stefan Kasper8, Everett E Vokes9, Caroline Even10, Francis Worden11, Nabil F Saba12, Lara Carmen Iglesias Docampo13, Robert Haddad14, Tamara Rordorf15, Naomi Kiyota16, Makoto Tahara17, Manish Monga18, Mark Lynch18, Li Li18, Robert L Ferris19.   

Abstract

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting. © AlphaMed Press 2018.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29866947      PMCID： PMC6221824          DOI： 10.1634/theoncologist.2017-0674

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  7 in total

1.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Authors:  Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Authors:  Kevin J Harrington; Robert L Ferris; George Blumenschein; A Dimitrios Colevas; Jérôme Fayette; Lisa Licitra; Stefan Kasper; Caroline Even; Everett E Vokes; Francis Worden; Nabil F Saba; Naomi Kiyota; Robert Haddad; Makoto Tahara; Viktor Grünwald; James W Shaw; Manish Monga; Mark Lynch; Fiona Taylor; Michael DeRosa; Laura Morrissey; Kim Cocks; Maura L Gillison; Joël Guigay
Journal:  Lancet Oncol       Date:  2017-06-23       Impact factor: 41.316

3.  Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.

Authors:  Jean-Pascal Machiels; Somasundaram Subramanian; Agnes Ruzsa; Gabor Repassy; Igor Lifirenko; Annika Flygare; Per Sørensen; Tina Nielsen; Steen Lisby; Paul M J Clement
Journal:  Lancet Oncol       Date:  2011-03-04       Impact factor: 41.316

Review 4.  Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.

Authors:  Diocésio A P de Andrade; Jean-Pascal Machiels
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

5.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

6.  Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Sadamoto Zenda; Yusuke Onozawa; Narikazu Boku; Yoshiyuki Iida; Mitsuru Ebihara; Tetsuro Onitsuka
Journal:  Jpn J Clin Oncol       Date:  2007-07       Impact factor: 3.019

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245
  7 in total
  22 in total

Review 1.  Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.

Authors:  Jaimin J Patel; Dylan A Levy; Shaun A Nguyen; Hannah M Knochelmann; Terry A Day
Journal:  Head Neck       Date:  2019-11-24       Impact factor: 3.147

2.  Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.

Authors:  Xiao Yu; Xiaolei Su; Ling Fang; Honglei Zhang; Xi Chen; Yu Pu; Hongyi Liu; Rui Guo
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-01       Impact factor: 3.236

Review 3.  Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.

Authors:  Jong Chul Park; Hari N Krishnakumar; Srinivas Vinod Saladi
Journal:  Curr Oncol       Date:  2022-06-08       Impact factor: 3.109

4.  Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer.

Authors:  Robert L Ferris; Jessica Moskovitz; Sheryl Kunning; Ayana T Ruffin; Carly Reeder; James Ohr; William E Gooding; Seungwon Kim; Brian J Karlovits; Dario A A Vignali; Umamaheswar Duvvuri; Jonas T Johnson; Daniel Petro; Dwight E Heron; David A Clump; Tullia C Bruno; Julie E Bauman
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 5.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

Review 6.  Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.

Authors:  K Devaraja
Journal:  Pharmaceut Med       Date:  2019-08

7.  CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma.

Authors:  Rehana Hewavisenti; Angela Ferguson; Angela Hong; Umaimainthan Palendira; Kevin Wang; Deanna Jones; Thomas Gebhardt; Jarem Edwards; Mei Zhang; Warwick Britton; Jean Yang
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

8.  Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Authors:  Robert Haddad; Fernando Concha-Benavente; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Stefan Kasper; Everett E Vokes; Francis Worden; Nabil F Saba; Makoto Tahara; Vijayvel Jayaprakash; Mark Lynch; Li Li; Maura L Gillison; Kevin J Harrington; Robert L Ferris
Journal:  Cancer       Date:  2019-06-27       Impact factor: 6.860

Review 9.  Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Edith Borcoman; Gregoire Marret; Christophe Le Tourneau
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

10.  Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.

Authors:  Marco C Merlano; Anna M Merlotti; Lisa Licitra; Nerina Denaro; Elena Fea; Danilo Galizia; Massimo Di Maio; Claudia Fruttero; Paola Curcio; Stefania Vecchio; Elvio G Russi; Renzo Corvò
Journal:  Clin Transl Radiat Oncol       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.